Alnylam Pharmaceuticals

Leader in #RNAiTherapeutics, having pioneered this innovative approach to silencing the genes that cause disease. Community guidelines:

[Alnylam Pharmaceuticals @Alnylam]

We’re proud to share that Muthiah (Mano) Manoharan has received the 2026 Khorana Prize from @RoySocChem, recognizing innovation at the interface of chemistry and biology. His pioneering work in nucleic acid chemistry has helped advance RNA-based medicines. Congrats, Mano!

[Alnylam Pharmaceuticals @Alnylam]

Delayed transthyretin-mediated amyloidosis cardiomyopathy diagnosis can lead to a 17% increase in 30-day readmissions.

Join @BeckersHR & Alnylam for a discussion with @advocatehealth, @UChicagoMed & @StLukesHealth to learn about the benefit of pharmacy-cardiology collaboration.

[Alnylam Pharmaceuticals @Alnylam]

We’re pleased to share a pooled analysis evaluating an investigational RNAi therapeutic when added on to RAAS inhibitors in patients with hypertension, including those with reduced kidney function.

Learn more: https://t.co/z0dCXOBDIR

[Alnylam Pharmaceuticals @Alnylam]

We were proud to be back on the court supporting @SpOlympicsMA and partnering again with Heller’s Angels, our longtime Special Olympics MA teammates. Thanks to everyone who played, donated, and cheered us on! #BioBall2026

[Alnylam Pharmaceuticals @Alnylam]

Join our #PNS2026 medical symposium for expert perspectives on multidisciplinary diagnosis, monitoring and care of patients with #ATTR #amyloidosis with neurologic and cardiac manifestations. https://t.co/1ZSyiKMxXp

For healthcare professionals and registered congress attendees

[Alnylam Pharmaceuticals @Alnylam]

Living with disease is noisy. The sounds of doctor visits, tests, managing medication, and declining things you want to do can mute the joy of life. But what happens when disease is silenced?

#SilenceDisease #AmplifyLife #RNAi #RNAiTherapeutics

[Alnylam Pharmaceuticals @Alnylam]

Nearly 40 of us walked Castle Island in Boston for the @HDSA #TeamHopeWalk last weekend, raising awareness for #HuntingtonsDisease. Thank you to everyone who joined and donated! Learn more at https://t.co/xW8l1MBr8L

[Alnylam Pharmaceuticals @Alnylam]

Early diagnosis is critical in managing a #RareDisease like primary #hyperoxaluria type 1 (PH1). Left undiagnosed, patients are at increased risk for complications. Learn from Dr. David J. Sas, pediatric nephrologist, in an episode of Medical Stories. https://t.co/erwqn03RNR

[Alnylam Pharmaceuticals @Alnylam]

We announced an AI collaboration with Inceptive to accelerate #RNAi therapeutic discovery.

By combining our RNAi platform and 20+ years of data with Inceptive’s #AI models, we aim to bring RNAi-based medicines to patients sooner.

A step forward in our Alnylam 2030 strategy.

[Alnylam Pharmaceuticals @Alnylam]

Living an amplified life with disease means your disease doesn’t dominate your day-to-day, allowing you to focus on doing what you love with the people who matter most. Helping people get to that place is why we’ve pioneered #RNAiTherapeutics.

#SilenceDisease #AmplifyLife

[Alnylam Pharmaceuticals @Alnylam]

This June, we’re proud to stand alongside and celebrate the LGBTQ+ community. Led by SAGA, our LGBTQ+ employee resource network, we’re coming together to reaffirm our commitment to equality, visibility, and belonging for all. Happy Pride!

#Pride2026 #PrideMonth #LGBTQ

[Alnylam Pharmaceuticals @Alnylam]

Applications are open for our US Clinical Fellowship Program for Academic Year 2027-2028.

Eligible ACGME-accredited institutions can apply for funding to advance physician training in the diagnosis, treatment, and research of ATTR.

Application window: June 1 - August 28, 2026

[Alnylam Pharmaceuticals @Alnylam]

HCPs: The burden of living with acute hepatic #porphyria (AHP) can greatly impact your patients’ quality of life. People living with AHP may have higher risk of long-term complications that have an immense emotional toll including depression and anxietyHCPs: The burden of living with acute hepatic #porphyria (AHP) can greatly impact your patients’ quality of life. People living with AHP may have higher risk of long-term complications that have an immense emotional toll including depression and anxietyHCPs: The burden of living with acute hepatic #porphyria (AHP) can greatly impact your patients’ quality of life. People living with AHP may have higher risk of long-term complications that have an immense emotional toll including depression and anxietyHCPs: The burden of living with acute hepatic #porphyria (AHP) can greatly impact your patients’ quality of life. People living with AHP may have higher risk of long-term complications that have an immense emotional toll including depression and anxiety.

[Alnylam Pharmaceuticals @Alnylam]

We believe all patients, regardless of their diagnosis, have the potential to benefit from the promise that #RNAiTherapeutics hold to #SilenceDisease and #AmplifyLife. That’s why we’ve pioneered this innovative approach and are working to bring it to as many patients as possible.

[Alnylam Pharmaceuticals @Alnylam]

We were proud to host @Amyloidosis_ARC this month, building on momentum from the Alnylam Global Advisory Summit. Together, we worked to define the shared priorities for our collaboration, with a focus on improving care for patients with ATTR-CM.

[Alnylam Pharmaceuticals @Alnylam]

Looking back on #HeartFailure26, conversations highlight scientific progress to address unmet needs in transthyretin #amyloidosis with cardiomyopathy (ATTR-CM). As the leader in #RNAi therapeutics, we remain committed to advancing innovation to help improve outcomes for patients.

[Alnylam Pharmaceuticals @Alnylam]

Managing a #RareDisease like primary #hyperoxaluria type 1 (PH1) can be difficult, so it’s helpful to work with patient advocacy groups to answer questions and get more information. Hear from Kim Hollander of @OHFTweet in an episode of Medical Stories. https://t.co/erwqn03RNR

[Alnylam Pharmaceuticals @Alnylam]

On #WorldClinicalTrialsDay, Carol Pitcher-Towner, Head of Development Programmes at Alnylam, asks an important question: “Who is represented in the data?”

In rare diseases, inclusion and trust are critical to research that truly reflects the communities it serves.

[Alnylam Pharmaceuticals @Alnylam]

At Alnylam, responsible business practices are essential to creating lasting impact. Our 2025 Corporate Responsibility Report highlights progress across patients, science, employees, communities, governance, and the environment.

#CorporateResponsibility #CSR #ESG

[Alnylam Pharmaceuticals @Alnylam]

Today, Alnylam colleagues are in #PurpleForPorphyria! 💜

Solving the puzzle of porphyria is complex, but in collaboration with @GlobalPorphyria for #GlobalPorphyriaDay, we’re helping piece it together. 🧩

#StandWithGlobalPorphyria #LightUpForPorphyria #RareDisease